CPS’ Post

🏆 This CPS study recently won gold: https://lnkd.in/gs_avQTp “Maximizing Cost Savings: The Impact of Specialty Pharmacist Interventions at a Community Oncology Center" is among the first studies with data proving specialty pharmacists: ✅ Improve medication adherence, ✅ Enhance medication safety, AND ✅ Drive cost savings. In this case, pharmacist interventions helped our client save $700,503 in less than five years. That's why the research recently won the Gold Award for Best Poster at Pharmacy Quality Alliance's Annual Conference. Read the impressive story behind the study: https://lnkd.in/gs_avQTp

Pharmacists are critical to implementing safe and high-quality use of antineoplastic agents and need to stay up to date with best practices for implementing oncology stewardship activities from an operational and clinical standpoint. This topic will help fill the gap between current and ideal practice by reviewing examples and best practice recommendations that pharmacists can implement in collaboration with interprofessional team members to improve resource utilization, patient safety, and quality of care. I have participated in a webinar organized by NCCN with the title NCCN Pharmacy Updates: Oncology Stewardship: Best Practices For Pharmacist In Optimizing Patient Safety and Quality of Care, where my goal in participating in this webinar is to describe oncology stewardship and the role of pharmacists in developing and leading oncology stewardship efforts, Implement oncology stewardship strategies including dose rounding and site of care standardization, and apply best practices to improve the use of antineoplastic agents with the goal of improving resource utilization, patient safety, and quality of care.

Bridging Clinical Research and Pharmacy Practice: The Evolving Role of Oncology Pharmacists: Scott Soefje highlights how oncology pharmacists can advance patient-centered care and drive innovation in clinical research. #finance #pharmacy #lifesciences

🔍 Bridging the Gap: Real-World Effectiveness in Multiple Myeloma Management 🌐💉 In the dynamic landscape of multiple myeloma (MM) treatment, a recent study by Alissa Visram, MD, MPH, sheds light on the crucial disparity between clinical trial efficacy and real-world effectiveness. The study, presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, delves into the outcomes of MM patients treated with standard-of-care regimens. By analyzing standard-of-care regimens via a comprehensive meta-analysis, the research team uncovered significant efficacy and effectiveness differences between the ideal clinical trial setting and real-world scenarios. Key Findings: 1️⃣ Efficacy-Effectiveness Gap: Real-world patients experienced a lower PFS and OS compared to highly selected patients in clinical trials for 6 out of 7 MM regimens evaluated. 2️⃣ Pomalidomide Plus Dexamethasone Exception: The regimen showed a trend of performing better in the real world, emphasizing the need for individualized considerations. 3️⃣ Risk Discrepancy: The risk of progression or death was 44% higher in real-world settings, and the risk of death was 75% higher compared to patients in clinical trials. These findings underscore the importance of utilizing real-world data to inform treatment decisions. Dr. Visram emphasizes the need for future trials to adopt more pragmatic designs and inclusive eligibility criteria to reduce the efficacy-effectiveness gap. Understanding the real-world effectiveness of MM treatments is crucial for both policy makers and clinicians, guiding informed decisions in an era of evolving and complex therapies. Stay informed, stay empowered! 💪🔬 #MultipleMyeloma #ClinicalTrials #RealWorldEvidence Helpful Links: https://lnkd.in/ejMcYrNZ https://lnkd.in/eYH3q6PG

When you see a headline like "60% of Young People With COVID Vaccine-induced Myocarditis Showed Heart Damage 6 Months Later" (https://lnkd.in/gjHwMRak), it's good to know that there is a company like Cardiol Therapeutics developing treatments to address the very high number of damaged young hearts. Cardiol's (NASDAQ: CRDL) (TSX: CRDL) Chief Medical Officer and Head of Research & Development Andrew Hamer on the company's latest milestone in clinical trials: "Reaching this milestone is integral to enhancing our understanding of the therapeutic impact of CardiolRx™ in acute myocarditis, a debilitating and potentially life-threatening inflammatory heart disease that significantly impairs cardiac function and patient quality of life. With top-line results expected early next year, the data from the ARCHER trial is anticipated to offer key insights concerning the effects of CardiolRx™ on myocardial recovery." #heartdisease #myocarditis #pericarditis #hearthealth #therapeutics #clinicaltrials #research

System C acquires CIS Oncology to expand medicine management - Digital Health System C's acquisition of CIS Oncology marks a pivotal expansion in medicines management, enhancing the prescription journey for clinicians and oncologists. This integration will streamline chemotherapy and non-chemotherapy drug prescriptions, reinforcing System C’s commitment to seamless, patient-centered care. With CIS Oncology’s ChemoCare and the upcoming ChemoPRO app, patients will gain instant access to their medical information, fostering better communication with healthcare professionals. This collaboration aims to improve patient outcomes through digitization and coordinated care, aligning with System C's dedication to the NHS and innovative healthcare solutions. #HealthcareIT #DigitalHealth #ePrescribing #PatientCare #Oncology #HealthTech #NHS ai.mediformatica.com #oncology #cisoncology #systemc #health #management #prescribing #acquisition #chemotherapy #medicine #patientrecord #electronicpatientrecord #maternity #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4hozqwf)

Check out M-CERSI workshop “ADEPT 9 Enhancing Diversity in Therapeutics Development for Pediatric Patients”, which will be held at FDA Great Room (White Oak, MD) on September 6, 2024 (as well as virtually). Free but must register. The purpose is to solicit input from stakeholders on: 1) Increasing the enrollment of historically underrepresented population in pediatric clinical studies, and 2) Encouraging pediatric clinical study participation that reflects the prevalence of the other disease or condition among demographic subgroups, where appropriate and other topics.  More at: https://lnkd.in/ee4BTxZF

In a recently published article in Pharmacy Times, insights from the NCODA Oncology Institute panel discussion on equitable care highlights how medically integrated pharmacies (MIPs) and independent pharmacy networks can significantly enhance access to treatment. Learn strategies to overcome high costs, fragmented communication and how to ensure cancer patients receive the comprehensive care they need. Check out the article below! https://bit.ly/3ZJcstB

NCCN is providing a pharmacy update on PGx across the oncology landscape. It is free to attend this webinar. Please join! #pgx #pharmacogenomics #NCCN #oncology #genomics #precisionmedicine

Unique Oncology Center Model Fully Integrates, Empowers Pharmacists: The model implemented at City of Hope Chicago has been shown to improve provider workloads and enrich pharmacists’ work. #finance #pharmacy #lifesciences